Highly Selective and Potent Human β‐Secretase 2 (BACE2) Inhibitors against Type 2 Diabetes: Design, Synthesis, X‐ray Structure and Structure–Activity Relationship Studies
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Herein we present the design, synthesis, and biological evaluation of potent and highly selective β‐secretase 2 (memapsin 1, beta‐site amyloid precursor protein cleaving enzyme 2, or BACE 2) inhibitors. BACE2 has been recognized as an exciting new target for type 2 diabetes. The X‐ray structure of BACE1 bound to inhibitor 2 a {N3‐[(1 S,2 R)‐1‐benzyl‐2‐hydroxy‐3‐[[(1 S,2 S)‐2‐hydroxy‐1‐(isobutylcarbamoyl)propyl]amino]propyl]‐5‐[methyl(methylsulfonyl)amino]‐N1‐[(1 R)‐1‐phenylpropyl]benzene‐1,3‐dicarboxamide} containing a hydroxyethylamine isostere was determined. Based on this structure, a computational docking study was performed which led to inhibitor 2 a‐bound BACE2 models. These were used to optimize the potency and selectivity of inhibitors. A systematic structure–activity relationship study led to the identification of determinants of the inhibitors’ potency and selectivity toward the BACE2 enzyme. Inhibitors 2 d [N3‐[(1 S,2 R)‐1‐benzyl‐2‐hydroxy‐3‐[[(1 S,2 S)‐2‐hydroxy‐1‐(isobutylcarbamoyl)pentyl]amino]propyl]‐N1‐methyl‐N1‐[(1 R)‐1‐phenylpropyl]benzene‐1,3‐dicarboxamide; Ki=0.031 n m, selectivity over BACE1: ≈174 000‐fold] and 3 l [N1‐((2 S,3 R)‐3‐hydroxy‐1‐phenyl‐4‐((3‐(trifluoromethyl)benzyl)amino)butan‐2‐yl)‐N3,5‐dimethyl‐N3‐((R)‐1‐phenylethyl)isophthalamide; Ki=1.6 n m, selectivity over BACE1: >500‐fold] displayed outstanding potency and selectivity. Inhibitor 3 l is nonpeptide in nature and may pave the way to the development of a new class of potent and selective BACE2 inhibitors with clinical potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
APP Processing and Synaptic Function
Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., & Malinow, R. (2003) · Neuron · doi:10.1016/s0896-6273(03)00124-7 · Cited by 1,644
Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management
Chaudhury, A., Duvoor, C., Reddy Dendi, V. S., Kraleti, S., Chada, A., Ravilla, R., Marco, A., Shekhawat, N. S., Montales, M. T., Kuriakose, K., et al. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00006 · Cited by 1,500
Control of Peripheral Nerve Myelination by the ß-Secretase BACE1
Willem, M., Garratt, A. N., Novak, B., Citron, M., Kaufmann, S., Rittger, A., DeStrooper, B., Saftig, P., Birchmeier, C., & Haass, C. (2006) · Science · doi:10.1126/science.1132341 · Cited by 703
BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells
Rochin, L., Hurbain, I., Serneels, L., Fort, C., Watt, B., Leblanc, P., Marks, M. S., De Strooper, B., Raposo, G., & van Niel, G. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220748110 · Cited by 186
BACE1 Deficiency Causes Altered Neuronal Activity and Neurodegeneration
Hu, X., Zhou, X., He, W., Yang, J., Xiong, W., Wong, P., Wilson, C. G., & Yan, R. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1334-10.2010 · Cited by 162
Harrison, S. M., Harper, A. J., Hawkins, J., Duddy, G., Grau, E., Pugh, P. L., Winter, P. H., Shilliam, C. S., Hughes, Z. A., Dawson, L. A., et al. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(03)00227-6 · Cited by 152
Cited by
Investigational BACE inhibitors for the treatment of Alzheimer’s disease
Imbimbo, B. P., & Watling, M. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1683160 · Cited by 132
Amyloid aggregates accumulate in melanoma metastasis modulating YAP activity
Matafora, V., Farris, F., Restuccia, U., Tamburri, S., Martano, G., Bernardelli, C., Sofia, A., Pisati, F., Casagrande, F., Lazzari, L., et al. (2020) · The EMBO Reports · doi:10.15252/embr.202050446 · Cited by 44
A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer’s Disease
Ettcheto, M., Busquets, O., Espinosa-Jiménez, T., Verdaguer, E., Auladell, C., & Camins, A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200211121416 · Cited by 13
BACE2 suppression in mice aggravates the adverse metabolic consequences of an obesogenic diet
Díaz-Catalán, D., Alcarraz-Vizán, G., Castaño, C., de Pablo, S., Rodríguez-Comas, J., Fernández-Pérez, A., Vallejo, M., Ramírez, S., Claret, M., Parrizas, M., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101251 · Cited by 10
Metadata
- Authors
- Ghosh, A. K., Brindisi, M., Yen, Y., Lendy, E. K., Kovela, S., Cárdenas, E. L., Reddy, B. S., Rao, K. V., Downs, D., Huang, X., Tang, J., & Mesecar, A. D.
- Venue
- ChemMedChem
- Publisher
- Wiley
- Published
- 2019-02-05
- Volume
- 14
- Issue
- 5
- Pages
- 545-560
- ISSN
- 1860-7179 (ISSN-L)
- 1860-7187
- OpenAlex
- W2909123853
- Cited by
- 22
- References
- 7
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Highly Selective and Potent Human β‐Secretase 2 (BACE2) Inhibitors against Type 2 Diabetes: Design, Synthesis, X‐ray Structure and Structure–Activity Relationship Studies. https://app.cochat.ai/papers/10.1002/cmdc.201800725
- The paper
- Ghosh, A. K., Brindisi, M., Yen, Y., Lendy, E. K., Kovela, S., Cárdenas, E. L., Reddy, B. S., Rao, K. V., Downs, D., Huang, X., Tang, J., & Mesecar, A. D. (2019). Highly Selective and Potent Human β‐Secretase 2 (BACE2) Inhibitors against Type 2 Diabetes: Design, Synthesis, X‐ray Structure and Structure–Activity Relationship Studies. ChemMedChem. https://doi.org/10.1002/cmdc.201800725
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.